XTALPI (02228) surged over 6%, and as of press time, the stock was up 6% to HK$9.18 with trading volume reaching HK$1.782 billion.

On the news front, on August 20, XTALPI announced the signing of a Memorandum of Understanding (MOU) with leading South Korean pharmaceutical company Dong-A ST. The two parties will leverage XTALPI's AI+ robotics R&D platform, combining their respective strengths to jointly develop innovative therapies targeting immune and inflammatory diseases.

This collaboration will utilize XTALPI's intelligent drug discovery platform driven by quantum physics, artificial intelligence (AI), and robotic experiments. Both companies will jointly identify targets and design and develop candidate drugs with first-in-class or best-in-class potential from scratch.

Previously, XTALPI issued a profit alert, expecting comprehensive income for the first half of the year to be no less than RMB 500 million, representing a year-on-year increase of at least approximately 387%. The company is expected to turn from loss to profit, recording a net profit of no less than RMB 50 million, marking the group's first-ever semi-annual profit achievement.

The expected improvement in financial performance during the period is primarily attributed to the group's collaboration with DoveTree. Based on its end-to-end artificial intelligence drug discovery platform and comprehensive "AI+robotics" technology, the group provides drug discovery solutions and services to DoveTree, driving significant revenue growth through this partnership.